166 related articles for article (PubMed ID: 8653708)
1. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
[TBL] [Abstract][Full Text] [Related]
2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
[TBL] [Abstract][Full Text] [Related]
5. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
Lebowitz PF; Davide JP; Prendergast GC
Mol Cell Biol; 1995 Dec; 15(12):6613-22. PubMed ID: 8524226
[TBL] [Abstract][Full Text] [Related]
6. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
7. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
[TBL] [Abstract][Full Text] [Related]
8. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
10. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
Du W; Lebowitz PF; Prendergast GC
Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
[TBL] [Abstract][Full Text] [Related]
11. Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.
Lebowitz PF; Sakamuro D; Prendergast GC
Cancer Res; 1997 Feb; 57(4):708-13. PubMed ID: 9044849
[TBL] [Abstract][Full Text] [Related]
12. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
13. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
[TBL] [Abstract][Full Text] [Related]
14. [Farnesyl transferase inhibitors: one target may be found in another].
Mazières J; Pradines A; Favre G
Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on farnesyl transferase inhibitors in cancer therapy.
Mazieres J; Pradines A; Favre G
Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
17. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton.
Prendergast GC; Davide JP; deSolms SJ; Giuliani EA; Graham SL; Gibbs JB; Oliff A; Kohl NE
Mol Cell Biol; 1994 Jun; 14(6):4193-202. PubMed ID: 8196657
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
Zhang B; Prendergast GC; Fenton RG
Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
[TBL] [Abstract][Full Text] [Related]
19. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
